Anti-CGRP Antibodies: The First Migraine-Specific Prevention Drugs Work
A systematic review of 32 trials confirmed that all four anti-CGRP monoclonal antibodies effectively prevent both episodic and chronic migraine.
Quick Facts
What This Study Found
All four monoclonal antibodies targeting the CGRP pathway — eptinezumab, erenumab, fremanezumab, and galcanezumab — showed positive results for preventing both episodic and chronic migraine across phase II and III clinical trials. This review of 32 eligible randomized controlled trials collectively demonstrated that blocking CGRP signaling is an effective preventive strategy for migraine.
The review noted that phase III trials were also underway for cluster headache prevention, though results were still pending at the time. The authors flagged the importance of monitoring cardiovascular effects of long-term CGRP blockade, since CGRP plays a role in blood vessel dilation and cardiovascular protection.
Key Numbers
136 records screened · 32 eligible RCTs reviewed · 4 monoclonal antibodies evaluated · Effective in episodic and chronic migraine
How They Did This
Systematic search of PubMed and ClinicalTrials.gov for randomized controlled trials investigating anti-CGRP monoclonal antibodies for migraine and cluster headache prevention. From 136 records, 32 were eligible for inclusion. The review synthesized phase II and III trial data for all four anti-CGRP antibodies.
Why This Research Matters
Before anti-CGRP antibodies, migraine prevention relied on drugs originally developed for other conditions — blood pressure medications, antidepressants, and anti-seizure drugs — none specifically designed for migraine. The CGRP pathway represented the first migraine-specific preventive target, offering a new class of treatment for the estimated 1 billion people worldwide affected by migraine. This systematic review captured a pivotal moment just as these drugs were entering clinical practice.
The Bigger Picture
This review documents the validation of CGRP as the first migraine-specific drug target — a milestone in headache medicine. Since publication, all four antibodies have been FDA-approved and are now widely prescribed. The CGRP story has expanded further with oral CGRP receptor antagonists (gepants) and the recognition that CGRP-targeted therapy works for both acute treatment and prevention. However, questions about long-term cardiovascular safety of blocking a vasodilatory peptide remain relevant.
What This Study Doesn't Tell Us
Published in 2019 (accepted 2017), this review captures early clinical trial data and precedes much of the post-marketing real-world evidence now available. Long-term safety data — particularly cardiovascular effects of sustained CGRP blockade — was not yet available. The cluster headache data was limited to ongoing trials without results.
Questions This Raises
- ?What are the long-term cardiovascular consequences of chronically blocking CGRP, a peptide with cardioprotective functions?
- ?Do anti-CGRP antibodies work differently in cluster headache compared to migraine?
- ?How do the four anti-CGRP antibodies compare to each other in terms of efficacy and safety?
Trust & Context
- Key Stat:
- 4 out of 4 antibodies effective Every anti-CGRP monoclonal antibody tested — eptinezumab, erenumab, fremanezumab, and galcanezumab — showed positive preventive results across multiple phase II/III trials
- Evidence Grade:
- This is a strong-grade systematic review of 32 randomized controlled trials from PubMed and ClinicalTrials.gov, providing high-quality synthesized evidence for the efficacy of anti-CGRP antibodies in migraine prevention.
- Study Age:
- Published in 2019 (accepted 2017), this review captured the clinical trial evidence just as anti-CGRP antibodies were entering the market. All four drugs have since been FDA-approved, and extensive real-world data now supplements these trial results.
- Original Title:
- CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
- Published In:
- Cephalalgia : an international journal of headache, 39(3), 374-389 (2019)
- Authors:
- Khan, Sabrina, Olesen, Astrid, Ashina, Messoud(9)
- Database ID:
- RPEP-04275
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
What is CGRP and why does blocking it prevent migraines?
CGRP (calcitonin gene-related peptide) is a neuropeptide released during migraine attacks that causes blood vessel dilation and transmits pain signals. CGRP levels spike during migraines and drop when treatment works. Blocking CGRP with antibodies prevents these pain cascades from starting, reducing the frequency and severity of attacks.
Are these anti-CGRP drugs available now?
Yes, all four are FDA-approved: erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). Three are self-administered monthly injections, while eptinezumab is given as a quarterly IV infusion. They are typically prescribed for people with frequent migraines who haven't responded well to other preventive treatments.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04275APA
Khan, Sabrina; Olesen, Astrid; Ashina, Messoud. (2019). CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.. Cephalalgia : an international journal of headache, 39(3), 374-389. https://doi.org/10.1177/0333102417741297
MLA
Khan, Sabrina, et al. "CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.." Cephalalgia : an international journal of headache, 2019. https://doi.org/10.1177/0333102417741297
RethinkPeptides
RethinkPeptides Research Database. "CGRP, a target for preventive therapy in migraine and cluste..." RPEP-04275. Retrieved from https://rethinkpeptides.com/research/khan-2019-cgrp-a-target-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.